Centessa Pharmaceuticals (CNTA) Revenue & Revenue Breakdown
Centessa Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$6.88M
Main Segment (Y)
Lixivaptan
Main Geography (Y)
Lixivaptan
Centessa Pharmaceuticals Revenue by Period
Centessa Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.88M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Centessa Pharmaceuticals generated $6.88M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Centessa Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.91M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Centessa Pharmaceuticals generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Centessa Pharmaceuticals Revenue Breakdown
Centessa Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 |
|---|---|
| Lixivaptan | $200.00M |
Centessa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 21: Lixivaptan (100.00%).
Centessa Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 |
|---|---|
| Lixivaptan | $200.00M |
Centessa Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 21: Lixivaptan (100.00%).
Centessa Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| TRDA | Entrada Therapeutics | $129.01M | $94.69M |
| GNFT | Genfit | $28.57M | $17.08M |
| TARS | Tarsus Pharmaceuticals | $17.45M | $40.81M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| OPT | Opthea | $108.41K | $61.27K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| NUVL | Nuvalent | - | - |
| IRON | Disc Medicine | - | - |
| ERAS | Erasca | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| HLVX | HilleVax | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
CNTA Revenue FAQ
What is Centessa Pharmaceuticals’s yearly revenue?
Centessa Pharmaceuticals's yearly revenue for 2023 was $6.88M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CNTA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Centessa Pharmaceuticals’s quarterly revenue?
Centessa Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). CNTA's quarterly revenue for Q4 2023 was $6.91M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Centessa Pharmaceuticals’s revenue growth rate?
Centessa Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Centessa Pharmaceuticals’s revenue streams?
Centessa Pharmaceuticals's revenue streams in c 21 are Lixivaptan
What is Centessa Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Centessa Pharmaceuticals was Lixivaptan. This segment made a revenue of $200M, representing 100.00% of the company's total revenue.